Moderna (MRNA) Revenue — Quarter Ended Jun 30, 2023
Revenue declined sharply in the current quarter. The decrease was steeper than the prior quarter and much steeper than the same quarter last year.
Key takeaway
Quarter ended Jun 30, 2023 · FY2023 Q2
Revenue declined sharply in the current quarter. The decrease was steeper than the prior quarter and much steeper than the same quarter last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$344M
Revenue reported for this quarter.
Quarter-over-quarter
-81.5%
Change from the immediately preceding quarter.
Year-over-year
-92.8%
Change from the comparable year-ago quarter.
Trailing four quarters
$10.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2022 | $3.4B | -32.3% |
| Dec 31, 2022 | $5.1B | -29.5% |
| Mar 31, 2023 | $1.9B | -69.3% |
| Jun 30, 2023 | $344M | -92.8% |
Revenue performance
Reported revenue fell compared to the immediately preceding quarter. The decline also deepened relative to the same quarter one year earlier.
Quarterly comparison
Revenue was lower than both the prior quarter and the year-ago quarter. The sequential decline was less severe than the year-over-year drop.
What to watch
The filing context does not provide specific causes for the revenue change.